Aurobindo Pharma Limited’s board will meet in early December to formalize a succession plan necessitated by an impending exit of managing director Narayanan Govindarajan, company officials said during a call to discuss Q2 FY22 performance.
Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit
Vaxxinity COVID-19 Vaccine Plans Hit Roadblock
Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock
